KR20170010764A - 신규한 항-ｒｎｆ43 항체 및 사용 방법 - Google Patents

신규한 항-ｒｎｆ43 항체 및 사용 방법 Download PDF

Info

Publication number
KR20170010764A
KR20170010764A KR1020167032459A KR20167032459A KR20170010764A KR 20170010764 A KR20170010764 A KR 20170010764A KR 1020167032459 A KR1020167032459 A KR 1020167032459A KR 20167032459 A KR20167032459 A KR 20167032459A KR 20170010764 A KR20170010764 A KR 20170010764A
Authority
KR
South Korea
Prior art keywords
antibody
rnf43
seq
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167032459A
Other languages
English (en)
Korean (ko)
Inventor
맨디 분탄라르트
딥티 록캄
데이비드 리우
스코트 제이. 딜라
모네트 오제이
Original Assignee
애브비 스템센트알엑스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 스템센트알엑스 엘엘씨 filed Critical 애브비 스템센트알엑스 엘엘씨
Publication of KR20170010764A publication Critical patent/KR20170010764A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A61K47/48615—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A61K47/48592—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167032459A 2014-04-21 2015-04-21 신규한 항-ｒｎｆ43 항체 및 사용 방법 Withdrawn KR20170010764A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982294P 2014-04-21 2014-04-21
US61/982,294 2014-04-21
PCT/US2015/026904 WO2015164392A2 (en) 2014-04-21 2015-04-21 Novel antii-rnf43 antibodies and methods of use

Publications (1)

Publication Number Publication Date
KR20170010764A true KR20170010764A (ko) 2017-02-01

Family

ID=54333409

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032459A Withdrawn KR20170010764A (ko) 2014-04-21 2015-04-21 신규한 항-ｒｎｆ43 항체 및 사용 방법

Country Status (18)

Country Link
US (1) US20170073430A1 (enExample)
EP (1) EP3134121A4 (enExample)
JP (1) JP2017518040A (enExample)
KR (1) KR20170010764A (enExample)
CN (1) CN106714831A (enExample)
AU (1) AU2015249887A1 (enExample)
BR (1) BR112016024525A2 (enExample)
CA (1) CA2946308A1 (enExample)
CL (2) CL2016002667A1 (enExample)
CR (1) CR20160486A (enExample)
DO (1) DOP2016000283A (enExample)
EA (1) EA201692100A8 (enExample)
IL (1) IL248399A0 (enExample)
MA (1) MA39896A (enExample)
MX (1) MX2016013857A (enExample)
PH (1) PH12016502061A1 (enExample)
SG (1) SG11201608715WA (enExample)
WO (1) WO2015164392A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
TW201800420A (zh) * 2016-05-20 2018-01-01 艾伯維史坦森特瑞斯有限責任公司 抗ascl1抗體及使用方法
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
JP7305543B2 (ja) * 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP2020518584A (ja) * 2017-05-02 2020-06-25 中外製薬株式会社 細胞傷害誘導治療剤
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
WO2020014271A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
CA3118692A1 (en) * 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
WO2020257758A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
EP4288458A1 (en) * 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
JP2024510291A (ja) 2021-03-16 2024-03-06 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫疾患を治療するための二機能性分子
CN113372447A (zh) * 2021-05-26 2021-09-10 重庆中元汇吉生物技术有限公司 抗pivka-ii单克隆抗体及其应用
CN118043482A (zh) * 2021-09-28 2024-05-14 保罗·谢勒学院 用于预测被诊断患有癌症的患者对采用靶向cck2-r的化合物进行的治疗和/或成像的响应的方法，以及用于对癌症进行选择性治疗和/或成像的方法的化合物
WO2024025878A2 (en) * 2022-07-25 2024-02-01 Memorial Sloan-Kettering Cancer Center Manufacturing processes for adoptive cell therapies
CN116120444A (zh) * 2023-02-28 2023-05-16 中国人民解放军军事科学院防化研究院 一种用于检测SARS-CoV-2病毒N蛋白的纳米抗体及检测卡制备
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
CN118652345B (zh) * 2024-06-28 2025-04-15 杭州华葵金配生物科技有限公司 幽门螺旋杆菌b型尿素酶抗体及其应用
CN119462949B (zh) * 2025-01-09 2025-04-01 中国农业科学院农业质量标准与检测技术研究所 一种抗β-内酰胺酶的抗体或其抗原结合片段、生物产品及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1513934T1 (sl) * 2002-06-06 2011-06-30 Oncotherapy Science Inc Geni in polipeptidi, povezani s humanimi raki kolona
CL2007001536A1 (es) * 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
CN109111523B (zh) * 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
ES2797533T3 (es) * 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43

Also Published As

Publication number Publication date
WO2015164392A2 (en) 2015-10-29
PH12016502061A1 (en) 2016-12-19
EP3134121A4 (en) 2017-11-08
DOP2016000283A (es) 2016-11-30
US20170073430A1 (en) 2017-03-16
CR20160486A (es) 2017-02-20
SG11201608715WA (en) 2016-11-29
IL248399A0 (en) 2016-11-30
WO2015164392A8 (en) 2016-12-29
MX2016013857A (es) 2017-07-14
WO2015164392A3 (en) 2015-12-23
CL2016002667A1 (es) 2017-07-07
JP2017518040A (ja) 2017-07-06
EA201692100A8 (ru) 2018-11-30
AU2015249887A1 (en) 2016-11-03
EP3134121A2 (en) 2017-03-01
BR112016024525A2 (pt) 2017-10-10
MA39896A (fr) 2017-03-01
CA2946308A1 (en) 2015-10-29
CN106714831A (zh) 2017-05-24
EA201692100A1 (ru) 2017-02-28
CL2017003240A1 (es) 2018-06-01

Similar Documents

Publication Publication Date Title
AU2018223053B2 (en) Novel modulators and methods of use
KR20170010764A (ko) 신규한 항-ｒｎｆ43 항체 및 사용 방법
JP6515111B2 (ja) 新規の抗クローディン抗体および使用方法
JP6010241B2 (ja) Ｄｌｌ３モジュレーター及び使用方法
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
KR20160097336A (ko) 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
JP2018529656A (ja) 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法
KR20160046914A (ko) 신규한 ｓｅｚ6 조절물질 및 사용방법
KR20180088445A (ko) 신규한 항-클라우딘 항체 및 사용 방법
KR20160044042A (ko) 부위-특이적 항체 접합 방법 및 조성물
AU2016355206A1 (en) Novel anti-EMR2 antibodies and methods of use
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
AU2016377669A1 (en) Novel anti-MMP16 antibodies and methods of use
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies
HK1200174B (en) Dll3 modulators and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination